The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Boehringer discontinues brigimadlin while others continue to struggle.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.